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Abstract
Background: The aim of this study was to characterize the genetic etiology in a patient who presented with permanent
neonatal diabetes at 2 months of age.
Methodology/Principal Findings: Regulatory elements and coding exons 2 and 3 of the INS gene were amplified and
sequenced from genomic and complementary DNA samples. A novel heterozygous INS mutation within the terminal
intron of the gene was identified in the proband and her affected father. This mutation introduces an ectopic splice site
leading to the insertion of 29 nucleotides from the intronic sequence into the mature mRNA, which results in a longer and
abnormal transcript.
Conclusions/Significance: This study highlights the importance of routinely sequencing the exon-intron boundaries and
the need to carry out additional studies to confirm the pathogenicity of any identified intronic genetic variants.
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Introduction
Neonatal diabetes mellitus is a rare genetic disorder (1:100,000
live newborns) characterized by hyperglycemia and low insulin
levels presenting during the first 6 months of life [1]. The disease
can be clinically subdivided into transient (TNDM) and perma-
nent (PNDM) forms depending on whether or not insulin
dependence resolves in infancy.
In the last few years, a number of mutations in the preproinsulin
gene (INS) (summarized by Stoy et al) [2] have been found to be
the second most common cause of PNDM (12% according to
Edghill et al. and 24.3% according to Colombo et al.) [3,4].
Initially, heterozygous coding mutations were identified [1,3–7].
These mutations show a dominant inheritance and most of them
have been found to disrupt the folding and conformation of
proinsulin in vitro, thus inducing endoplasmatic reticulum (ER)
stress [4]. Clinical features of these patients suggest that birth
weight is similar [3] or slightly higher [4] compared to birth weight
in patients with mutations in KCNJ11 and ABCC8, although
patients with heterozygous mutations in the INS gene tend to be
diagnosed slightly later [2–4].
Subsequently, recessively-acting biallelic INS mutations were
described which result in decreased insulin biosynthesis through
distinct mechanisms, including gene deletion, abnormal transcrip-
tion, lack of the translation initiation signal, and altered mRNA
stability. Compared to patients carrying heterozygous INS
mutations, patients with biallelic INS mutations show a markedly
different clinical phenotype, with lower birth weight (median:
1680 g vs 2530 g) and an earlier age at diagnosis (median: 1 week
vs 10 weeks) [8,9].
We report the identification of a PNDM patient carrying a
heterozygous mutation within the terminal intron of the INS gene.
The mutation results in aberrant splicing by introducing an
ectopic splice site leading to the insertion of 29 nucleotides from
the intron into the mature mRNA and therefore resulting in a
longer and abnormal transcript.
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Results and Discussion
Since the first description of INS as a PNDM gene in 2007,
several dominantly-acting mutations (23 missense, one nonsense,
one insertion/deletion) [2] and a further ten recessively-acting
mutations have been reported to cause neonatal diabetes [8]. They
are located in all regions of the preproinsulin gene, including the
promoter (6 mutations), signal peptide (3 mutations), B-chain (12
mutations), C-peptide (2 mutations), A-chain (8 mutations), and
both pairs of basic amino acids flanking the C-peptide (2
mutations) [2]. In vitro studies for some of these mutations have
confirmed [4,10,11] or discarded [12] their pathogenic effect, thus
highlighting the importance in vitro studies for the functional
characterization of genetic variants identified in rare diseases,
where familial co-segregation studies cannot usually be performed
since there is often one affected individual at each family.
On the other side, no intronic INS mutation affecting splicing
has been described to date. The majority of splicing-disrupting
mutations detected in other genes are single nucleotide substitu-
tions within the consensus sequence of the splice sites and result in
either complete exon skipping, use of a nearby pseudo 39 or 59
splice site, or retention of the mutated intron [13]. Less frequently,
the mutations create an ectopic splice site or activate a cryptic
splice site, thereby changing the overall splicing pattern of the
mutant transcript [14].
In the present study, we have identified the first heterozygous
intronic mutation (c.188-31G.A) in the INS gene causing
neonatal diabetes in both the proband and her affected father
(Figure 1). The variant is located 31 bp proximal to exon 3 within
the polypyrimidine tract of intron 2, which normally determines
the strength of the splice acceptor site. The mutation turns the
dinucleotide (Y)nGG into (Y)nAG, creating a typical consensus 39
splice site, as in silico analysis predicted. Indeed, the confidence
value for the new ectopic splice site was higher than that for the
regular splice site (0.52 vs 0.18) so that the splicing machinery
would preferentially recognise the new splice site and read the last
29 bp of intron 2 as exonic sequence (Figure 2).
RNA studies carried out on a lymphoblastoid cell line obtained
from the proband confirmed this hypothesis (Figure 3). The 29 bp
insertion alters the reading frame in the mutant transcript which is
not predicted to be subject to nonsense-mediated [15] nor non-
stop decay [16] since the frame shift would not generate a
premature termination codon and the new stop codon would be
located within the 39 UTR (19 aminoacids downstream the
original stop codon). In fact, according to the intensity of the bands
obtained after RT-PCR (results not shown), the mutant transcript
was processed more efficiently than the normal transcript, as
predicted by in silico studies. The mutant proprotein would
normally translocate into the ER as the signal peptide is intact. In
silico 3D structure studies of its amino acid sequence (p.Val63-
Glufs*78) predicted the removal of the three conserved disulfide
bonds (B7-A7, B19-A20, A6-A11) and the creation of a new one
(B19-N25), suggesting that mutant protein would fail to fold
properly (Figures 4 and 5). However, the B-chain would be normal
and Arg31,32 cleavage site remains accessible (Figure 6).
Although it has not yet been established clearly the sequence of
events leading to initiation of B-chain folding, formation of inter-
and intrachain disulfide bond and proinsulin cleavage, misfolding
would disrupt trafficking from the endoplasmic reticulum which
would ultimately lead to b-cell dysfunction and eventual cell death
[17], as it happens with a number of other previously described
heterozygous INS mutations [2].
Clinically, the birth weight of the proband was normal.
Although birth weight in patients carrying INS heterozygous
coding mutations tend to be low [2], some cases with normal birth
weight have been reported [4]. It has been proposed that the
growth retardation at birth might be partly explained by the
gender of the patient, being more severe in males than in females
[18]. In our experience, however, low birth weight is usually
associated with recessively-inherited INS mutations that lead to a
nearly complete insulin deficiency [8], whereas heterozygous
mutations leading to a gradual and progressive decrease of insulin
secretion secondary to ER stress-mediated b-cell apoptosis are
associated with normal or slightly reduced birth weight [3–5]. The
proband was diagnosed at 5 weeks of age, slightly earlier that the
reported median age of 10 weeks [2,3], but this may reflect an
increased awareness due to the positive family history.
Figure 1. Partial pedigree of the family with intronic INS
mutation. (N, Normal allele; M, mutation). Solid black-filled shapes
represent patients with permanent neonatal diabetes. Age at diagnosis
and birth weight are shown below the symbols (NA: not available).
doi:10.1371/journal.pone.0029205.g001
Figure 2. Schematic representation of the intron-exon struc-
ture of the INS gene and the splicing changes due to the found
mutation. Exons are represented by white boxes, introns as lanes, the
intronic insertion at transcript level is indicated by a grey box and the
new aberrant sequence is shown in black. The splicing event is shown
by a broken lane. The mutation position is indicated in red. Y: C/T.
doi:10.1371/journal.pone.0029205.g002
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In summary, we report a novel mutation type at the
preproinsulin gene leading to neonatal diabetes. Our finding
highlights the importance of routinely sequencing exon-intron
boundaries and the need to carry out additional RNA studies to
confirm the pathogenicity of any identified intronic genetic
variants.
Figure 3. Sequence of amplified cDNA obtained from RNA of lymphoblastoid cells. Upper sequence is obtained from patient’s
immortalized cells. Lower panel, the sequence obtained from unaffected control lymphoblastoid cells.
doi:10.1371/journal.pone.0029205.g003
Figure 4. Tertiary structure of the wild-type proinsulin (PDB ref:
2KQP). Disulfide bonds (B7-A7, B19-A20, A6-A11) are shown in green.
doi:10.1371/journal.pone.0029205.g004
Figure 5. Predicted tertiary structure of the aberrant protein.
The new disulfide bond (B19-N25) is shown in green. Unpaired cysteine
residues (B7 and N34) are shown in cyan. N25 and N34: cysteine at
position 25 and 34 of the ‘‘new’’ aminoacidic sequence. N34 correspond
to Cys72.
doi:10.1371/journal.pone.0029205.g005
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Materials and Methods
Ethics statement
The study was carried out in accordance with the Declaration of
Helsinki. This study was approved by the Medical Ethics
Commission, Hospital de Cruces. The study also complied with
Spanish laws and regulations, accreditation standards and
institutional policies. Participants gave written informed consent,
with parents consenting on behalf of the proband.
Case report
The proband, of Caucasian origin, presented with permanent
diabetes at 2 months of age (blood glucose 8.3–10 mmol/L). She
was born to non-consanguineous parents at 40 weeks gestation with
a normal birth weight (3050 g, 20.66 SDS). Pregnancy was
uneventful. Pancreatic autoantibodies (ICA and IAA) were absent at
diagnosis and she was started on subcutaneous insulin (initial daily
requirement 0.4 U/kg). There was a strong family history of early-
onset diabetes on the paternal side. Her father was diagnosed with
permanent neonatal diabetes (PNDM) at 31 days of life and two
paternal aunts died from diabetic ketoacidosis within the first year.
The proband is currently 10.5 years and remains on intensive
insulin therapy (1.1 U/kg/day). Diabetes has never remitted.
Molecular genetic analysis
Genomic DNA from proband and parents was extracted from
peripheral leukocytes using standard procedures using QIAamp
DNAMini Kit (QIAGEN, Du¨ren, Germany). Regulatory elements
and coding exons 2 and 3 of the INS gene were amplified and
sequenced as previously described [8]. Additionally, 100 unrelated,
non-diabetic individuals were studied, and served as control group.
In silico studies
The potential effect on mRNA splicing of the c.188-31G.A
mutation was analyzed using the splice site prediction of CBS-Gene
Finding and Intron Splice Site Prediction (http://www.cbs.dtu.dk/
services/NetGene2/) web interface.
RNA analysis
Cell lines were established from peripheral blood lymphocytes
derived from the proband and an unaffected control by EBV
transformation. Cell lines were maintained in 16 RPMI-1640
(Gibco Life Technologies, Paisley, UK), supplemented with 10%
fetal calf serum (Gibco Life Technologies, Paisley, UK). Total
RNA was extracted from approximately 16106 EBV-transformed
lymphoblastoid cellsusing QiaAmp Blood RNA mini kit (QIA-
GEN, Du¨ren, Germany). Synthesis of complementary DNA
(cDNA) and amplification of the fragment of interest were
performed from mRNA using the One Step RT-PCR (QIAGEN,
Du¨ren, Germany) (primers and conditions are available on
request). RT-PCR products were run on 4% agarose gels and
the amplicons were excised and purified by QIAquick Gel
Extraction Kit (QIAGEN; Du¨ren, Germany). The purified
amplicons were sequenced by standard methods on an
ABI3130XL (Applied Biosystems, Warrington, UK).
Protein Structure Prediction
3D structure of the mutant protein was predicted using I-
TASSER fold recognition method [19]. The predicted structure
was superimposed with the normal proinsulin structure (PDB ref:
2KQP) using TM-Align [20] and visualised with PyMOL
Software (www.pymol.org).
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